Patent intelligence · EP
EP 1297826
Pharmazeutische Zusammensetzung zur nasalen Verabreichung enthaltend einen NK-2 Antagonisten
Pharmazeutische Zusammensetzung zur nasalen Verabreichung enthaltend einen NK-2 Antagonisten
Patent details — EP 1297826
- Jurisdiction
- EP
- Status
- expired
- Grant date
- Apr 2, 2003
- Expiration
- Mar 28, 2023
- Applicant
- MENARINI RICERCHE SPA [IT]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 16 A I, A61K 47/ 32 A I, A61K/4732
Quick answer
EP 1297826 (Pharmazeutische Zusammensetzung zur nasalen Verabreichung enthaltend einen NK-2 Antagonisten) is held by MENARINI RICERCHE SPA [IT]. Status: expired. Granted Apr 2, 2003. Expires Mar 28, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MENARINI RICERCHE SPA [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 16 A I, A61K 47/ 32 A I, A61K/4732, A61K/90043, A61K/91635
More from MENARINI RICERCHE SPA [IT]
Related pharmaceutical patents in our USPTO index.
-
WO 2024252263
COMPOSITIONS SOLIDES DE DICHLORHYDRATE D'ÉLACESTRANT, LEURS PROCÉDÉS DE FABRICATION ET MÉTHODES DE TRAITEMENT LES UTILISANT
granted -
WO 2024023766
POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K
granted -
CA 3259243
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2
granted -
CA 3259252
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3
granted -
WO 2022029639
FORMULATIONS PHARMACEUTIQUES AMÉLIORÉES COMPRENANT DES INHIBITEURS DE PI3K
granted -
US 2021015826
ANTICANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
granted -
US 2020040086
PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY
granted -
CA 3102476
ASSOCIATIONS PHARMACEUTIQUES
granted
Frequently asked questions
What is US patent 1297826?
EP 1297826 (Pharmazeutische Zusammensetzung zur nasalen Verabreichung enthaltend einen NK-2 Antagonisten) is held by MENARINI RICERCHE SPA [IT]. Status: expired. Granted Apr 2, 2003. Expires Mar 28, 2023 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 1297826?
MENARINI RICERCHE SPA [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 1297826 expire?
Our index shows an expiration date of Mar 28, 2023 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.